A PYMNTS Company

Roche receives FTC second request for proposed acquisition of Illumina

 |  March 13, 2012

Roche has announced that the FTC has issued a second request for information on its proposed acquisition of Illumina. Under the terms of the tender offer, Roche will purchase all outstanding shares of Illumina for $44.50 in cash. Switzerland-based Roche is the world’s largest biotech company. The request concerns Roche’s microarray business. The Hart-Scott-Rodino waiting period will be delayed until 10 days after Roche has substantially complied with the second request.

Full content: Marketwatch


Related contentNew Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)